Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform rating. Why Oppenheimer Is Bullish on ALMS Due to concerns about Alumis' cash ...
Opinion
3dOpinion
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?
Alumis Inc. recently reported first-quarter 2026 results, with revenue of US$1.74 million versus US$17.39 million a year earlier and a net loss of US$93.05 million compared with US$98.96 million ...
Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...
Alan Colowick, a director at $ALMS, bought 16,104 shares of the company on 04-01-2025 for an estimated $112,309. This trade was reported by Quiver Quantitative using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results